

Palliative Therapie des kolorektalen Karzinoms – ein Entitätsbericht

Dr. Frank Strohbach, Berlin

28. März 2009


MVZ Ärzteforum Seestrassen Berlin




Palliative Therapie des CRC

- 109 beteiligte Praxen
- 2.870 gemeldete Patienten
- 1.837 dokumentierte Patienten
- 1.645 auswertbare Patienten
- 809 verstorbene Patienten
(vollständiges follow up)


Vortherapien (adjuvant)




Palliative Chemotherapien



Palliative Chemotherapien – 1st-line




Palliative Chemotherapien – 2nd-line



Gesamtüberleben ab Erstdiagnose

Gesamtüberleben ab Erstdiagnose - Patienten


n = 1645 Min = 0.7 Max = 215.5



n = 1.645


42,7 Monate

Gesamtüberleben ab Therapiebeginn (1st-line)



n = 1.640
1st-line
Chemotherapie
21,7 Monate

Gesamtüberleben 1st-line



n = 1.640

n = 1.532

21,7 Monate

Kombinationstherapie


n = 108

23,1 Monate

Monotherapie

Gesamtüberleben 1st-line

Gesamtüberleben (Kaplan-Meyer) nach Prognose für alle Therapien




n = 23,2 Monate
geringes Risiko
(EORTC: 15,0 Mo.)

n = 18,8 Monate
intermediäres Risiko
(EORTC: 11,0 Mo.)

n = 11,0 Monate
hohes Risiko
(EORTC: 6,0 Mo.)

Gesamtüberleben 1st-line




21,7 Monate alle
n = 1.640

23,5 Monate
Oxaliplatin (n = 639)


23,1 Monate
Antikörper (n = 733)

20,0 Monate
Irinotecan (n = 846)

Ansprechen 1st-line (Irinotecan)



Gesamtüberleben 1st-line (Irinotecan)



20,0 Monate
alle (n = 846)

28,1 Monate
FOLFIRI+Cetuximab
(n = 9)


24,4 Monate
FOLFIRI+Bevacizumab
(n = 230)

23,2 Monate
FOLFIRI (n = 89)


22,3 Monate
Irinotecan/AIO+Bev.
(n = 372)

17,0 Monate
Irinotecan/AIO (n = 317)

Ansprechen 1st-line (Oxaliplatin)



Gesamtüberleben 1st-line (Oxaliplatin)



23,5 Monate
alle (n = 639)


24,9 Monate
FOLFOX 4 (n = 94)

22,6 Monate
FOLFOX 4 +
Bevacizumab (n = 14)

22,3 Monate
FUFOX (n = 208)

19,0 Monate
FUFOX+Bev. (n = 12)

Gesamtüberleben 2nd-line



12,4 Monate
alle (n = 1.038)


12,8 Monate
Oxaliplatin (n = 433)

11,5 Monate
Irinotecan (n = 508)

10,1 Monate
Irinotecan/Cetuximab
(n = 242)

Überleben nach Hauttoxizität

Gesamtüberleben (Kaplan-Meyer) nach Hauttoxizität für alle Therapien



Cetuximab 2nd-line

Grad 0: 6,0 Mo.

Grad 1: 10,0 Mo.

Grad 2: 14,0 Mo.

Grad 3: 18,3 Mo.

Grad 4: 3,0 Mo.